Routine board appointment with no immediate trading catalyst. Monitor for any strategic shifts given Cohen's deep healthcare investing background, but no near-term action warranted.
Price Chart
Executive Summary
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manager, to its board of directors effective June 12, 2026. The appointment is routine with standard non-employee director compensation and a sign-on RSU grant of $887,000 vesting over three years.
Key Facts
- Dr. Matt Cohen appointed as director effective June 12, 2026
- Cohen brings 25+ years of healthcare investing experience, currently Managing Director at Vida Ventures
- Sign-on RSU grant valued at $887,000 vesting over three years
- Standard non-employee director compensation; no family relationships or arrangements
Financial Impact
No material financial impact; sign-on RSU grant of $887,000 is standard director compensation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879407-26-000050 |
| Document: 0000879407-26-000050-index-headers.html | 0000879407-26-000050 |
| Document: 0000879407-26-000050-index.html | 0000879407-26-000050 |
| Document: 0000879407-26-000050.txt | 0000879407-26-000050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $82.76 $67.74 | ▼ −18.15% | ▼ −17.65% | $64.19 (−22.44%) |
Aug 20, 2026 6w ago | Insider Cluster | $87.47 $88.59 | ▲ +1.28% | ▲ +0.17% | $64.19 (−26.61%) |
Jun 16, 2026 15w ago | 8-K | $81.04 $79.81 | ▼ −1.52% | ▼ −0.48% | $64.19 (−20.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access